|
Age, mean (range)
|
64.34 (36–86 years)
|
|
Gender, n (%)
|
|
Male
|
24 (68.6%)
|
|
Female
|
11 (31.4%)
|
|
Rai staging system, n (%)
|
|
0
|
8 (22.9%)
|
|
I
|
3 (8.6%)
|
|
II
|
3 (8.6%)
|
|
III
|
10 (28.6%)
|
|
IV
|
11 (31.4%)
|
|
Modified Rai staging system, n (%)
|
|
Low-risk group
|
8 (22.9%)
|
|
Intermediate-risk group
|
6 (17.1%)
|
|
High-risk group
|
21 (60.0%)
|
|
Binet staging system, n (%)
|
|
A
|
12 (34.3%)
|
|
B
|
2 (5.7%)
|
|
C
|
21 (60.0%)
|
|
Splenomegaly, n (%)
|
|
Yes
|
19 (54.3%)
|
|
No
|
16 (45.7%)
|
|
Lymphadenopathy, n (%)
|
|
Yes
|
11 (31.4%)
|
|
No
|
24 (68.6%)
|
|
Hepatomegaly, n (%)
|
|
Yes
|
0 (0%)
|
|
No
|
35 (100%)
|
|
WBC count × 103/μL, median (IQR)
|
45 (22–112)
|
|
Platelets × 103/μL, median (IQR)
|
131 (95–167)
|
|
≥ 100
|
n, 24 (68.6%)
|
|
< 100
|
n, 11 (31.4%)
|
|
Hemoglobin g/dL, median (IQR)
|
10.7 (9.9–13.2)
|
|
≥ 11
|
n, 15 (42.9%)
|
|
< 11
|
n, 20 (57.1%)
|
|
ALC × 103/μL, median (IQR)
|
35.9 (18.4–101)
|
|
ANC × 103/μL, median (IQR)
|
4.2 (3.6–11)
|
|
PLR × 103/μL, median (IQR)
|
3.2 (1.3–8.1)
|
|
NLR × 103/μL, median (IQR)
|
0.15 (0.09–0.18)
|
|
CD38 (%), median (IQR)
|
3.0 (1.0–6.0)
|
|
CD25 (%), median (IQR)
|
6.0 (1.5–10.0)
|
|
Double positive CD56/CD117, median (IQR)
|
0.1 (0.1–0.4)
|
